Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Merck
Johnson and Johnson
McKinsey
Mallinckrodt

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERLOTINIB HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Erlotinib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00026338 Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Completed NCIC Clinical Trials Group Phase 3 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.
NCT00030446 Erlotinib and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCIC Clinical Trials Group Phase 2 2002-01-01 RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with carboplatin may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining erlotinib and carboplatin in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
NCT00030485 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCIC Clinical Trials Group Phase 2 2002-01-01 RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.
NCT00030485 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed National Cancer Institute (NCI) Phase 2 2002-01-01 RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.
NCT00030498 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed National Cancer Institute (NCI) Phase 1 2001-12-01 Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Erlotinib Hydrochloride

Condition Name

Condition Name for Erlotinib Hydrochloride
Intervention Trials
Non-Small Cell Lung Cancer 111
Lung Cancer 65
Carcinoma, Non-Small-Cell Lung 50
Pancreatic Cancer 47
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Erlotinib Hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 388
Lung Neoplasms 336
Pancreatic Neoplasms 80
Carcinoma 79
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Erlotinib Hydrochloride

Trials by Country

Trials by Country for Erlotinib Hydrochloride
Location Trials
Korea, Republic of 98
France 92
Australia 91
Germany 88
United Kingdom 87
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Erlotinib Hydrochloride
Location Trials
California 158
Texas 142
New York 128
Florida 110
Illinois 106
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Erlotinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Erlotinib Hydrochloride
Clinical Trial Phase Trials
Phase 4 18
Phase 3 87
Phase 2/Phase 3 11
[disabled in preview] 488
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Erlotinib Hydrochloride
Clinical Trial Phase Trials
Completed 384
Active, not recruiting 106
Recruiting 98
[disabled in preview] 145
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Erlotinib Hydrochloride

Sponsor Name

Sponsor Name for Erlotinib Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 158
Genentech, Inc. 105
Hoffmann-La Roche 71
[disabled in preview] 92
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Erlotinib Hydrochloride
Sponsor Trials
Other 741
Industry 502
NIH 159
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Dow
McKinsey
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.